Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Eikelboom, Willem S.
van Rooij, Jeroen G. J.
van den Berg, Esther
Coesmans, Michiel
Jiskoot, Lize C.
Singleton, Ellen
Ossenkoppele, Rik
van Swieten, John C.
Seelaar, Harro
Papma, Janne M.
and
Lanctôt, Krista
2018.
Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer’s Disease: A Case Report.
Journal of Alzheimer's Disease,
Vol. 66,
Issue. 4,
p.
1363.
Jeste, Dilip V.
2019.
International Psychogeriatrics 2019: the year in review.
International Psychogeriatrics,
Vol. 31,
Issue. 12,
p.
1681.
Sajatovic, Martha
2019.
Commentary on “Caregiver-Care Recipient Relationship Closeness is Associated With Neuropsychiatric Symptoms in Dementia”.
The American Journal of Geriatric Psychiatry,
Vol. 27,
Issue. 4,
p.
360.
McDermott, Cara L.
and
Gruenewald, David A.
2019.
Pharmacologic Management of Agitation in Patients with Dementia.
Current Geriatrics Reports,
Vol. 8,
Issue. 1,
p.
1.
Keszycki, Rachel M.
Fisher, Daniel W.
and
Dong, Hongxin
2019.
The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions.
Frontiers in Pharmacology,
Vol. 10,
Issue. ,
Eikelboom, Willem S.
Singleton, Ellen
van den Berg, Esther
Coesmans, Michiel
Mattace Raso, Francesco
van Bruchem, Rozemarijn L.
Goudzwaard, Jeannette A.
de Jong, Frank Jan
Koopmanschap, Marc
den Heijer, Tom
Driesen, Jan J. M.
Vroegindeweij, Lilian J. H. M.
Thomeer, Elsbeth C.
Hoogers, Susanne E.
Dijkstra, Anke A.
Zuidema, Sytse U.
Pijnenburg, Yolande A. L.
Scheltens, Philip
van Swieten, John C.
Ossenkoppele, Rik
and
Papma, Janne M.
2019.
Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study.
Alzheimer's Research & Therapy,
Vol. 11,
Issue. 1,
Kales, Helen C.
Gitlin, Laura N.
and
Lyketsos, Constantine G.
2019.
When Less is More, but Still Not Enough: Why Focusing on Limiting Antipsychotics in People With Dementia Is the Wrong Policy Imperative.
Journal of the American Medical Directors Association,
Vol. 20,
Issue. 9,
p.
1074.
Ohno, Yukihiro
Kunisawa, Naofumi
and
Shimizu, Saki
2019.
Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects.
Frontiers in Pharmacology,
Vol. 10,
Issue. ,
Aerts, Liesbeth
Cations, Monica
Harrison, Fleur
Jessop, Tiffany
Shell, Allan
Chenoweth, Lynn
and
Brodaty, Henry
2019.
Why deprescribing antipsychotics in older people with dementia in long‐term care is not always successful: Insights from the HALT study.
International Journal of Geriatric Psychiatry,
Vol. 34,
Issue. 11,
p.
1572.
Piau, Antoine
Rumeau, Pierre
Nourhashemi, Fati
and
Martin, Maria Soto
2019.
Information and Communication Technologies, a Promising Way to Support Pharmacotherapy for the Behavioral and Psychological Symptoms of Dementia.
Frontiers in Pharmacology,
Vol. 10,
Issue. ,
Bessey, Laurel J.
and
Walaszek, Art
2019.
Management of Behavioral and Psychological Symptoms of Dementia.
Current Psychiatry Reports,
Vol. 21,
Issue. 8,
Cloutier, Martin
Gauthier‐Loiselle, Marjolaine
Gagnon‐Sanschagrin, Patrick
Guerin, Annie
Hartry, Ann
Baker, Ross A.
Duffy, Ruth
Gwin, Keva
and
Sanon Aigbogun, Myrlene
2019.
Institutionalization risk and costs associated with agitation in Alzheimer's disease.
Alzheimer's & Dementia: Translational Research & Clinical Interventions,
Vol. 5,
Issue. 1,
p.
851.
Aigbogun, Myrlene Sanon
Cloutier, Martin
Gauthier-Loiselle, Marjolaine
Guerin, Annie
Ladouceur, Martin
Baker, Ross A.
Grundman, Michael
Duffy, Ruth A.
Hartry, Ann
Gwin, Keva
Fillit, Howard
and
Jensen-Dahm, Christina
2020.
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review.
Journal of Alzheimer’s Disease,
Vol. 77,
Issue. 3,
p.
1181.
Yunusa, Ismaeel
and
El Helou, Marie Line
2020.
The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use.
Frontiers in Pharmacology,
Vol. 11,
Issue. ,
Azarpazhooh, M. Reza
Amiri, Amin
Morovatdar, Negar
Steinwender, Sandy
Rezaei Ardani, Amir
Yassi, Nawaf
Biller, Jose
Stranges, Saverio
Tokazebani Belasi, Masoud
Neya, Sepideh Kazemi
Khorram, Bita
Sheikh Andalibi, Mohammad Sobhan
Arsang-Jang, Shahram
Mokhber, Naghmeh
and
Di Napoli, Mario
2020.
Correlations between COVID-19 and burden of dementia: An ecological study and review of literature.
Journal of the Neurological Sciences,
Vol. 416,
Issue. ,
p.
117013.
Yan, Xu
Hu, Yue
Wang, Biyao
Wang, Sijian
and
Zhang, Xinwen
2020.
Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease.
Frontiers in Neuroscience,
Vol. 14,
Issue. ,
Muntsant, Aida
and
Giménez-Llort, Lydia
2020.
Impact of Social Isolation on the Behavioral, Functional Profiles, and Hippocampal Atrophy Asymmetry in Dementia in Times of Coronavirus Pandemic (COVID-19): A Translational Neuroscience Approach.
Frontiers in Psychiatry,
Vol. 11,
Issue. ,
Cunha, Sara
Forbes, Ben
Lobo, José Manuel Sousa
and
Silva, Ana Catarina
2020.
Thermosensitive Nasal In Situ Gels of Lipid-Based Nanosystems to Improve the Treatment of Alzheimer’s Disease.
p.
37.
Wang, Huali
2020.
Delirium: A suggestive sign of COVID-19 in dementia.
EClinicalMedicine,
Vol. 26,
Issue. ,
p.
100524.
Covino, Marcello
De Matteis, Giuseppe
Santoro, Michele
Sabia, Luca
Simeoni, Benedetta
Candelli, Marcello
Ojetti, Veronica
and
Franceschi, Francesco
2020.
Clinical characteristics and prognostic factors in COVID‐19 patients aged ≥80 years.
Geriatrics & Gerontology International,
Vol. 20,
Issue. 7,
p.
704.